Down-regulation by troglitazone of hepatic tumor necrosis factor-α and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes

Biochemical Pharmacology

Volumn 60, Issue 1, 2000, Pages 67-75

  Sigrist, Stephan ^a   Bedoucha, Marc ^a   Boelsterli, Urs A ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cytokines; Diabetes; Gene regulation; KKA(y) mice; Peroxisome proliferator activated receptor (PPAR ); Thiazolidinediones

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; LIVER; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERITONEUM MACROPHAGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CHROMANS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE EXPRESSION; HYPOGLYCEMIC AGENTS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, INBRED C57BL; RNA, MESSENGER; THIAZOLES; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034010651     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00299-9     Document Type: Article

References (44)

1. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:1998;241-252.
2. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha Direct role in obesity-linked insulin resistance . Science. 259:1993;87-91.
3. Hofmann C., Lorenz K., Braithwaite S.S., Colca J.R., Palazuk B.J., Hotamisligil G.S., Spiegelman B.M. Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology. 134:1994;264-270.
4. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 95:1995;2409-2415.
5. Kern P.A., Saghizadeh M., Ong J.M., Bosch R.J., Deem R., Simsolo R.B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 95:1995;2111-2119.
6. Miles P.D., Romeo O.M., Higo K., Cohen A., Rafaat K., Olefsky J.M. TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes. 46:1997;1678-1683.
7. Yang S.Q., Lin H.Z., Lane M.D., Clemens M., Diehl A.M. Obesity increases sensitivity to endotoxin liver injury Implications for the pathogenesis of steatohepatitis . Proc Natl Acad Sci USA. 94:1997;2557-2562.
8. Yamakawa T., Tanaka S.I., Yamakawa Y., Kiuchi Y., Isoda F., Kawamoto S., Okuda K., Sekihara H. Augmented production of tumor necrosis factor-alpha in obese mice. Clin Immunol Immunopathol. 75:1995;51-56.
9. Peraldi P., Xu M., Spiegelman B.M. Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling. J Clin Invest. 100:1997;1863-1869.
10. Ohsumi J., Sakakibara S., Yamaguchi J., Miyada K., Yoshioka S., Fujiwara T., Horikoshi H., Serizawa N. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology. 135:1994;2279-2282.
11. Szalkowski D., White-Carrington S., Berger J., Zhang B. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology. 136:1995;1474-1481.
12. Jiang C., Ting A.T., Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86.
13. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391:1998;79-82.
14. Zhu Y., Alvares K., Huang Q., Rao M.S., Reddy J.K. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem. 268:1993;26817-26820.
15. Fajas L., Auboeuf D., Raspé E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., Laville M., Fruchart J.C., Deeb S., Vidal-Puig A., Flier J., Briggs M.R., Staels B., Vidal H., Auwerx J. The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem. 272:1997;18779-18789.
16. Watkins P.B., Whitcomb R.W. Hepatic dysfunction associated with troglitazone. N Engl J Med. 338:1998;916-917.
17. Iwatsuka H., Shino A., Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinol Jpn. 17:1970;25-35.
18. Herberg L., Coleman D.L. Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism. 26:1977;59-99.
19. y mice. Am J Physiol. 271:1996;E333-E339.
20. y mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone. Arterioscler Thromb. 13:1993;302-309.
21. y mouse: Effects of pioglitazone on malonyl-CoA and diacylglycerol. Am J Physiol267: E95-E101, 1994.
22. y mice . Pharmacology. 54:1997;169-178.
23. Fujiwara T., Okuno A., Yoshioka S., Horikoshi H. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism. 44:1995;486-490.
24. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
25. Decker K.F. Bacterial endotoxin. Sipes I.G., McQueen C.A., Gandolfi A.J. Comprehensive Toxicology. Vol. 9:1997;433-446 Elsevier, Oxford.
26. Giorgini A.E., Beales P.E., Mire-Sluis A., Scott D., Liddi R., Pozzilli P. Troglitazone exhibits immunomodulatory activity on the cytokine production of activated human lymphocytes. Horm Metab Res. 31:1999;1-4.
27. Zhu Y., Qi C., Korenberg J.R., Chen X.N., Noya D., Rao M.S., Reddy J.K. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene Alternative promoter use and different splicing yield two mPPARγ isoforms . Proc Natl Acad Sci USA. 92:1995;7921-7925.
28. Vidal-Puig A., Jimenez-Linan M., Lowell B.B., Hamann A., Hu E., Spiegelman B., Flier J.S., Moller D.E. Regulation of PPAR γ gene expression by nutrition and obesity in rodents. J Clin Invest. 97:1996;2553-2561.
29. Young P.W., Buckle D.R., Cantello B.C., Chapman H., Clapham J.C., Coyle P.J., Haigh D., Hindley R.M., Holder J.C., Kallender H., Latter A.J., Lawrie K.W.M., Mossakowska D., Murphy G.J., Cox L.R., Smith S.A. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiondinated ligand for peroxisomal proliferator-activated receptor γ J Pharmacol Exp Ther. 284:1998;751-759.
30. Lichtman S.N., Wang J., Lemasters J.J. LPS receptor CD14 participates in release of TNF-α in RAW 264.7 and peritoneal cells but not in kupffer cells. Am J Physiol. 38:1998;G39-G46.
31. Decker K. Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J Biochem. 192:1990;245-261.
32. Decker T., Lohmann-Matthes M.L., Gifford G.E. Cell-associated tumor necrosis factor (TNF) is a killing mechanism of activated cytotoxic macrophages. J Immunol. 138:1987;957-962.
33. Solorzano C.C., Ksontini R., Pruitt J.H., Hess P.J., Edwards P.D., Kaibara A., Abouhamze A., Auffenberg T., Galardy R.E., Vauthey J.N., Copeland E.M. 3rd, Edwards C.K. 3rd, Lauwers G.Y., Clare-Salzer M., MacKay S.L., Moldawer L.L., Lazarus D.D. Involvement of 26-kDa cell-associated TNF-alpha in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J Immunol. 158:1997;414-419.
34. Hamada E., Nishida T., Uchiyama Y., Nakamura J., Isahara K., Kazuo H., Huang T.P., Momoi T., Ito T., Matsuda H. Activation of Kupffer cells and caspase-3 involved in rat hepatocyte apoptosis induced by endotoxin. J Hepatol. 30:1999;807-818.
35. Gordon H.M., Kucera G., Salvo R., Boss J.M. Tumor necrosis factor induces genes involved in inflammation, cellular and tissue repair, and metabolism in murine fibroblasts. J Immunol. 148:1992;4021-4027.
36. Diehl A.M., Rai R. Review Regulation of liver regeneration by pro-inflammatory cytokines . J Gastroenterol Hepatol. 11:1996;466-470.
37. Simpson K.J., Lukacs N.W., Colletti L., Strieter R.M., Kunkel S.L. Cytokines and the liver. J Hepatol. 27:1997;1120-1132.
38. Bradham C.A., Plümpe J., Manns M.P., Brenner D.A., Trautwein C. Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol. 38:1998;G387-G392.
39. Mehendale H.M. Role of hepatocellular regeneration and hepatolobular healing in the final outcome of liver injury. A two-stage model of toxicity. Biochem Pharmacol. 42:1991;1155-1162.
40. Chanda S., Mehendale H.M. Hepatic cell division and tissue repair A key to survival after liver injury . Mol Med Today. 2:1996;82-89.
41. 4 hepatotoxicity A novel dose-response . Toxicology. 118:1997;181-193.
42. Gitlin N., Julie N.L., Spurr C.L., Lim K.N., Juarbe H.M. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med. 129:1998;36-38.
43. Neuschwander-Tetri B.A., Isley W.L., Oki J., Ramrakhiani S., Quiason S.G., Phillips N.J., Brunt E.M. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med. 129:1998;38-41.
44. Shibuya A., Watanabe M., Fujita Y., Saigenji K., Kuwao S., Takahashi H., Takeuchi H. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care. 21:1998;2140-2143.